» Authors » Peter T Simpson

Peter T Simpson

Explore the profile of Peter T Simpson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 96
Citations 4297
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu L, Zhang J, Wood S, Newell F, Leonard C, Koufariotis L, et al.
BMC Genomics . 2024 Sep; 25(1):898. PMID: 39350042
Background: Lung cancer is a heterogeneous disease and the primary cause of cancer-related mortality worldwide. Somatic mutations, including large structural variants, are important biomarkers in lung cancer for selecting targeted...
2.
Joshi V, Beecher K, Lim M, Stacey A, Feng Y, Jat P, et al.
Int J Mol Sci . 2024 Apr; 25(7). PMID: 38612786
Brain metastasis is a significant challenge for some breast cancer patients, marked by its aggressive nature, limited treatment options, and poor clinical outcomes. Immunotherapies have emerged as a promising avenue...
3.
Fielding D, Lakis V, Dalley A, Chittoory H, Newell F, Koufariotis L, et al.
Cancers (Basel) . 2024 Feb; 16(4). PMID: 38398180
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is often the only source of tumor tissue from patients with advanced, inoperable lung cancer. EBUS-TBNA aspirates are used for the diagnosis, staging, and...
4.
Lim M, Fletcher N, Saunus J, McCart Reed A, Chittoory H, Simpson P, et al.
Mol Pharm . 2023 Nov; 20(12):6169-6183. PMID: 37970806
Breast cancer brain metastases (BM) are associated with a dismal prognosis and very limited treatment options. Standard chemotherapy is challenging in BM patients because the high dosage required for an...
5.
Fielding D, Dalley A, Singh M, Nandakumar L, Lakis V, Chittoory H, et al.
Front Oncol . 2023 Nov; 13:1259882. PMID: 37927461
Introduction: Tumour Mutation Burden (TMB) is a potential biomarker for immune cancer therapies. Here we investigated parameters that might affect TMB using duplicate cytology smears obtained from endobronchial ultrasound transbronchial...
6.
Causer A, Tan X, Lu X, Moseley P, Teoh S, Molotkov N, et al.
NPJ Precis Oncol . 2023 Sep; 7(1):89. PMID: 37704757
Immune checkpoint inhibitor (ICI) therapy has had limited success (<30%) in treating metastatic recurrent Head and Neck Oropharyngeal Squamous Cell Carcinomas (OPSCCs). We postulate that spatial determinants in the tumor...
7.
Nguyen H, Geukens T, Maetens M, Aparicio S, Bassez A, Borg A, et al.
Nat Commun . 2023 Jul; 14(1):4418. PMID: 37479706
Obesity is associated with an increased risk of developing breast cancer (BC) and worse prognosis in BC patients, yet its impact on BC biology remains understudied in humans. This study...
8.
Fielding D, Dalley A, Singh M, Nandakumar L, Lakis V, Chittoory H, et al.
Lung . 2023 Jul; 201(4):407-413. PMID: 37405466
Introduction: Maximising alternative sample types for genomics in advanced lung cancer is important because bronchoscopic samples may sometimes be insufficient for this purpose. Further, the clinical applications of comprehensive molecular...
9.
Fielding D, Dalley A, Singh M, Nandakumar L, Lakis V, Chittoory H, et al.
Cancer Cytopathol . 2023 Mar; 131(6):373-382. PMID: 36938641
Background: Cytology smears are commonly collected during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS TBNA) procedures but are rarely used for molecular testing. Studies are needed to demonstrate their great potential,...
10.
Stark Z, Boughtwood T, Haas M, Braithwaite J, Gaff C, Goranitis I, et al.
Am J Hum Genet . 2023 Mar; 110(3):419-426. PMID: 36868206
Australian Genomics is a national collaborative partnership of more than 100 organizations piloting a whole-of-system approach to integrating genomics into healthcare, based on federation principles. In the first five years...